Charani Ranasinghe

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

Google Scholar citation report

Citations : 2341

Journal of Vaccines & Vaccination received 2341 citations as per Google Scholar report

Journal of Vaccines & Vaccination peer review process verified at publons

25+ Million Website Visitors

Indexed In

Academic Journals Database
Open J Gate
Genamics JournalSeek
JournalTOCs
China National Knowledge Infrastructure (CNKI)
Scimago
Ulrich's Periodicals Directory
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
MIAR
University Grants Commission
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Tweets by Vaccine41931315

Open Access Journals

Charani Ranasinghe

Charani Ranasinghe

Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research, The Australian National University, Australia

Biography

Charani Ranasinghe completed her PhD from University of Western Australia. She is the Group Leader of the Molecular Mucosal Vaccine Immunology Group at the JCSMR, Australian National University. She was the first to discover that IL-13 plays an important role in modulating CD8 T cell avidity in a vaccine route dependent manner. Her team has recently developed two novel IL-4R antagonist and IL-13Ra2 adjuvanted vaccine platforms that can induce high quality systemic/ Mucosal CD8 T and B cell immunity.